CASPOFUNGIN ACETATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Caspofungin Acetate, and when can generic versions of Caspofungin Acetate launch?
Caspofungin Acetate is a drug marketed by Areva Pharms, Cipla, Fresenius Kabi Usa, Gland, Hengrui Pharma, Norvium Bioscience, and Xellia Pharms Aps. and is included in seven NDAs. There is one patent protecting this drug.
This drug has fourteen patent family members in fourteen countries.
The generic ingredient in CASPOFUNGIN ACETATE is caspofungin acetate. There are eight drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the caspofungin acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Caspofungin Acetate
A generic version of CASPOFUNGIN ACETATE was approved as caspofungin acetate by FRESENIUS KABI USA on December 30th, 2016.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CASPOFUNGIN ACETATE?
- What are the global sales for CASPOFUNGIN ACETATE?
- What is Average Wholesale Price for CASPOFUNGIN ACETATE?
Summary for CASPOFUNGIN ACETATE
International Patents: | 14 |
US Patents: | 1 |
Applicants: | 7 |
NDAs: | 7 |
Finished Product Suppliers / Packagers: | 7 |
Raw Ingredient (Bulk) Api Vendors: | 74 |
Clinical Trials: | 20 |
Patent Applications: | 775 |
Drug Prices: | Drug price information for CASPOFUNGIN ACETATE |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for CASPOFUNGIN ACETATE |
What excipients (inactive ingredients) are in CASPOFUNGIN ACETATE? | CASPOFUNGIN ACETATE excipients list |
DailyMed Link: | CASPOFUNGIN ACETATE at DailyMed |
Recent Clinical Trials for CASPOFUNGIN ACETATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Phase 4 |
European Organisation for Research and Treatment of Cancer - EORTC | Phase 3 |
Children's Oncology Group | Phase 3 |
Pharmacology for CASPOFUNGIN ACETATE
Drug Class | Echinocandin Antifungal |
Anatomical Therapeutic Chemical (ATC) Classes for CASPOFUNGIN ACETATE
Paragraph IV (Patent) Challenges for CASPOFUNGIN ACETATE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
CANCIDAS | for Injection | caspofungin acetate | 50 mg/vial and 70 mg/vial | 021227 | 1 | 2009-06-26 |
US Patents and Regulatory Information for CASPOFUNGIN ACETATE
CASPOFUNGIN ACETATE is protected by one US patents.
Patents protecting CASPOFUNGIN ACETATE
Caspofungin acetate formulations
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Areva Pharms | CASPOFUNGIN ACETATE | caspofungin acetate | POWDER;INTRAVENOUS | 211263-001 | Oct 1, 2021 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Gland | CASPOFUNGIN ACETATE | caspofungin acetate | POWDER;INTRAVENOUS | 207092-001 | Sep 29, 2017 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Cipla | CASPOFUNGIN ACETATE | caspofungin acetate | POWDER;INTRAVENOUS | 209489-002 | Jul 12, 2018 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Norvium Bioscience | CASPOFUNGIN ACETATE | caspofungin acetate | POWDER;INTRAVENOUS | 207650-002 | Sep 29, 2017 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for CASPOFUNGIN ACETATE
See the table below for patents covering CASPOFUNGIN ACETATE around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Poland | 2922530 | ⤷ Sign Up | |
European Patent Office | 2922530 | COMPOSITIONS D'ACÉTATE DE CASPOFUNGINE (CASPOFUNGIN ACETATE FORMULATIONS) | ⤷ Sign Up |
Slovenia | 2922530 | ⤷ Sign Up | |
Hungary | E032392 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for CASPOFUNGIN ACETATE
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0620232 | SPC/GB02/002 | United Kingdom | ⤷ Sign Up | A SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB02/002 GRANTED TO MERCK SHARP + DOHME, CORP IN RESPECT OF THE PRODUCT CASPOFUNGIN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY CASPOFUNGIN ACETATE, WHICH WAS ADVERTISED AS COMING INTO FORCE IN JOURNAL NO 5919 DATED 30 OCTOBER 2002 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, IT WILL EXPIRE ON 24 OCTOBER 2016. |
0620232 | C300076 | Netherlands | ⤷ Sign Up | PRODUCT NAME: CASPOFUNGINE, DESGEWENST IN DE VORM VAN EEN ZUURADDITIEZOUT, IN HET BIJZONDER CASPOFUNGINE ACETAAT; REGISTRATION NO/DATE: EU/1/01/196/001-003 20011024 |
0620232 | 44/2001 | Austria | ⤷ Sign Up | PRODUCT NAME: CASPOFUNGIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE CASPOFUNGINACETAT; REGISTRATION NO/DATE: EU/01/196/001-003 20011024 |
0620232 | 2001/029 | Ireland | ⤷ Sign Up | PRODUCT NAME: CASPOFUNGIN, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY CASPOFUNGIN ACETATE; REGISTRATION NO/DATE: EU/1/01/196/001-003 20011024; PAEDIATRIC INV. PLAN: P/30/2008 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |